Research programme: lung disorders therapy - Beth Israel Deaconess/SELECT Therapeutics

Drug Profile

Research programme: lung disorders therapy - Beth Israel Deaconess/SELECT Therapeutics

Alternative Names: Lung disorders therapy research programme - Beth Israel Deaconess/SELECT Therapeutics

Latest Information Update: 08 Nov 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beth Israel Deaconess Medical Center; SELECT Therapeutics (CEASED)
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Cystic fibrosis; Respiratory tract disorders

Most Recent Events

  • 08 Nov 2002 Discontinued - Preclinical for Asthma in USA (unspecified route)
  • 08 Nov 2002 Discontinued - Preclinical for Cystic fibrosis in USA (unspecified route)
  • 08 Nov 2002 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top